Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis

Drugs of Today

Volumn 46, Issue 5, 2010, Pages 315-325

  Vasiliou, Sylvia ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; KETOCONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELIN BASIC PROTEIN; NATALIZUMAB;

B LYMPHOCYTE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRADYCARDIA; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIPOPHILICITY; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RECURRENCE RISK; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77954726635     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.5.1497556     Document Type: Review

References (55)

1. Murray, T.J. Robert Carswell: The First Illustrator of MS. The International MS Journal 2009, 16: 98-101.
2. Barnett, M.H., Parrat, J.D.E, Pollard, J.D., Prineas, J.W. MS: Is it one disease? The International MS Journal 2009, 16: 57-65.
3. Albert, R., Hinterding, K., Brinkmann, V. et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 2005, 48(16): 5373-77.
4. Anada, Y., Igarashi, Y., Kihara, A. The immunomodulator FTY720 is phosphorylated and released from platelets. Eur J Pharmacol 2007, 568(1-3): 106-11. (Pubitemid 46976917)
5. Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., Seuwen, K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009, 5(6): 428-34.
6. Krump-Konvalinkova, V., Chwalla, I., Siess, W. FTY720 inhibits S1P-mediated endothelial healing: Relationship to S1P1-receptor surface expression. Biochem Biophys Res Commun 2008, 370(4): 603-8.
7. Deogracias, R., Matsumoto, T., Klein, C., Yazdani, M., Bibel, M., Barde, Y. FTY720 induces BDNF production in neuronal cell cultures. 60th Annu Meet Am Acad Neurol (AAN) (April 12-19, Chicago) 2008, Abst P07.123.
8. Bibel, M., Richter, J., Schrenk, K. et al. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 2004, 7(9): 1003-9.
9. Jung, C.G., Miron, V.E., Cook, S., Foster, C.A., Antel, J.P., Soliven, B. Pleiotropic actions of FTY720- phosphate in cells of oligodendroglial lineage. Multiple Scler 2006, 12(1, Suppl.): Abst P375.
10. Jung, C.G., Kim, H.J., Miron, V.E. et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007, 55(16): 1656-67.
11. Barske, C., Osinde, M., Klein, C., Mattes, H., Mir, A.K., Dev, K.K., Gasparini, F. FTY720 (fingolimod) and S1P-receptor 1 and 5 specific agonists increase the number of oligodendrocytes in vitro. 60th Annu Meet Am Acad Neurol (AAN) (April 12-19, Chicago) 2008, Abst P01.089.
12. Coelho, R.P., Payne, S.G., Bittman, R., Spiegel, S., Sato-Bigbee, C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007, 323(2): 626-35.
13. Miron, V.E., Darlington, P.J., Ludwin, S.K., Jarjour, A.A., Kennedy, T.E., Antel, J.P. The immunomodulator fingolimod (FTY720) increases myelin production following demyelination of organotypic cerebellar slices. 61st Annu Meet Am Acad Neurol (AAN) (April 25-May 2, Seattle) 2009, Abst S47.003.
14. Miron, V.E., Kennedy, T.E., Soliven, B., Antel, J.P. Dose- and treatment duration-dependent effects of FTY720 on human oligodendroglial process dynamics. 60th Annu Meet Am Acad Neurol (AAN) (April 12-19, Chicago) 2008, Abst P07.124.
15. Miron, V.E., Hall, J.A., Kennedy, T.E., Soliven, B., Antel, J.P. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am J Pathol 2008, 173:1143-52.
16. Kataoka, H., Seki, N., Shimano, K., Maeda, Y., Sugahara, K., Sugita, T., Chiba, K. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis (EAE) in mice. 9th World Congr Inflamm (July 6-10, Tokyo) 2009, Abst GA.14.07.
17. Gardell, S., Choi, J.W., Herr, D., Anliker, B., Lu, M., Kennedy, G., Chun, J. Evidence for neural S1P receptor signalling in EAE and FTY720 efficacy. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 11-14, Prague) 2007, Abst 243.
18. Pryce, G., Al-lzki, S., Baker, D., Giovannoni, G. Control of chronic relapsing progressive EAE with fingolimod. 60th Annu Meet Am Acad Neurol (AAN) (April 12-19, Chicago) 2008, Abst P01.092.
19. Jackson, S.J., Pryce, G., Al-lzki, S., Baker, D., Giovannoni, G. Fingolimod reduces axonal loss in relapsing secondary progressive EAE. 38th Annu Meet Soc Neurosci (November 15-19, Washington DC) 2008, Abst 116.11.
20. Schubart, A., Howard, L., Seabrook, T., Lange, T., Rausch, M., Mir, A.K. FTY720 suppresses ongoing EAE and promotes a remyelinating environment preventing axonal degeneration within the CNS. 60th Annu Meet Am Acad Neurol (AAN) (April 12-19, Chicago) 2008, Abst P06.166.
21. Seabrook, T. Schubart, A., Rausch, M., Mir, A.K. FTV720 suppresses established EAE and allows remyelination. Annu Meet Fed Clin Immunol Soc (FOCIS) (June 5-9, Boston) 2008, Abst Su.109.
22. Balatoni, B, Storch, M.K., Weissert, R., Foster, C.A. Oral fingolimod maintains and restores neuronal function in demyelinating models of multiple sclerosis, as assessed by somatosensory and visual evoked potentials. Multiple Scler 2006, 12(1, Suppl. ): Abst P791.
23. Storch, M.K., Rausch, M., Hiestand, P., Balatoni, B., Foster, C.A. FTY720 not only prevents EAE onset, as assessed by MRI, but also reverses established neurological deficits and extensive demyellnation. 21st Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (September 28-October 1, Thessaloniki) 2005, Abst P188.
24. Rausch, M., Kindler, D., Bolliger, S., Hiestand, P. Demonstration of the efficacy of FTV720 in acute EAE: Analysis of lesion load using USPIO- and gadolinium-enhanced MRI and correlation with neurological readouts. 21st Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (September 28-October 1, Thessaloniki) 2005, Abst P187.
25. Pachner, A., Apte, P., Brady, J., Li, L. Therapeutice effects of oral fingolimod (FTY720) in an animal model of the progressive disability of multiple sclerosis. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P06.213.
26. Kovarik, J.M., Schmouder, R., Barilla, D., Wang, Y., Kraus, G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol 2004, 57(5): 586-91.
27. Slade, A., Schmouder, R., Kovarik, J., Gschwind, H.-P., David, O. High bioavailability and long half-life of oral fingolimod (FTY720), an investigational treatment for multiple sclerosis. 61st Annu Meet Am Acad Neurol (AAN) (April 25-May 2, Seattle) 2009, Abst P07.144.
28. Kovarik, J.M., Schmouder, R., Barilla, D., Riviere, G.J., Wang, Y., Hunt, T. Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004, 44(5): 532-37.
29. Kovarik, J.M., Dole, K., Riviere, G.J. et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009, 49(2): 212-18.
30. Schmouder, R., Aradhye, S., O'Connor, P., Kappos, L. Pharmacodynamic effects of oral fingolimod (FTY720). Multiple Scler 2006, 12(1, Suppl. ): Abst P378.
31. Keezer, M.R., Lapierre, Y., Shames, I., Haegert, D., Bar-Or, A., Antel, J. Prolonged reduction in circulating lymphocytes after discontinuation of FTY720 (fingolimod): Possible relationship to duration of therapy. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst PD5.006.
32. Mehling, M., Fritz, S., Hilbert, P., Lindberg, R., Kuhle, J., Kappos, L., Hess, C. Cellular and humoral influenza vaccine-specific immune responses in patients with multiple sclerosis treated with FTY720 or interferon-beta. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P04.217.
33. Bar-Or, A., Arbour, N., McCrae, E., Regen, T., Touil, T., Newell, K., Antel, J.P. Effects of long-term fingolimod therapy on circulating mononuclear cell populations in multiple sclerosis. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 11-14, Prague) 2007, Abst 556.
34. Schmouder, R., Liu, C., David, O.J., Wang, N. Treatment with oral fingolimod (FTY720), 0.5 or 1.25 mg, for 14 days has no effect on airway resistance. 61st Annu Meet Am Acad Neurol (AAN) (April 25-May 2, Seattle) 2009, Abst P05.136.
35. Slade, A., Boulton, C., David, O.J., Dumortier, T., Schmouder, R. Effects of oral fingolimod (FTY720) on pulmonary function tests in patients with moderate asthma. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P01.175.
36. Radue, E.W., O'Connor, O., Antel, J. et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: MRI results of a placebo-controlled phase II study and active drug extension. Multiple Scler 2006, 12(1, Suppl. ): Abst P377.
37. Kappos, L., Radu, E.W., Antel, J. et al. Promising results with a novel oral immunomodulator - FTY720 - in relapsing multiple sclerosis. 21st Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (September 28-October 1, Thessaloniki) 2005, Abst 64.
38. O'Connor, P., Antel, J., Comi, G. et al. Phase II study with oral FTY720 in relapsing MS: Results of the dose-blinded active drug extension phase at 12 months. 21st Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (September 28-October 1, Thessaloniki) 2005, Abst 682.
39. Kappos, L., Antel, J., Comi, G. et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: 24-Month results of the phase II study. Multiple Scler 2006, 12(1, Suppl. ): Abst P376.
40. Montalban, X., O'Connor, P., Antel, J. et al. Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: Four-year results from a phase II extension. 61st Annu Meet Am Acad Neurol (AAN) (April 25-May 2, Seattle) 2009, Abst P06.128.
41. Pohlmann, H., Tang, D., Antel, J.P. et al. Statistical modelling of 24-months MRI and relapse data from a phase II trial with FTY720 (fingolimod) in relapsing MS. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (October 11-14, Prague) 2007, Abst 584.
42. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) (NCT00289978) www.ClinicalTrials.gov, accessed April 29, 2010.
43. Kappos, L., Radue, E.W., O'Connor, P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 2010, 362(5): 387-401.
44. Radue, E.W., O'Connor, P., Polman, C. et al. Oral fingolimod (FTY720) reduces inflammatory activity vs placebo in relopsing-remitting multiple sclerosis: 24-month MRI results from a randomized, double-blind, placebo-controlled, multicenter phase III study (FREEDOMS). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst S11.005.
45. Kappos, L., O'Connor, P., Polman, C. et al. Oral fingolimod (FTY720) vs. placebo in relapsing-remitting multiple sclerosis: 24-month clinical efficacy from a randomized, double-blind, placebo-controlled, multicenter phase III study (FREEDOMS). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst S11.004.
46. Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II) (NCT00355134). www.ClinicalTrials.gov, accessed April 29, 2010.
47. Calabresi, P.A., Goodin, D., Jeffery, D. et al. Oral fingolimod (FTY720) in relapsing-remitting multiple sclerosis: Baseline patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS II). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P05.038.
48. Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS II) (NCT00774670) www.ClinicalTrials.gov, accessed April 29, 2010.
49. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis with optional extension phase (TRANSFORMS) (NCT00340834) www.ClinicalTrials.gov, accessed April 29, 2010.
50. Cohen, J.A., Barkhof, F., Comi, G. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 2010, 362(5): 402-14.
51. Cohen, J.A., Pelletier, J., Kappos, L. et al. Oral fingolimod (FTY720) vs. interferon beta-1a in relapsing-remitting multiple sclerosis: Results from a phase III study (TRANSFORMS). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst S21.004.
52. Khatri, B., Barkhof, F., Comi, G. et al. Oral fingolimod (FTY720) reduces the rate of relapses that require steroid intervention or hospitalization compared with intramuscular interferon beta-1a: Results from a phase III study (TRANSFORMS) in multiple sclerosis. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P06.170.
53. Cohen, J., Barkhof, F., Comi, G. et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon beta-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities results from a phase III study (TRANSFORMS). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P06.137.
54. O'Connor, P., Polman, C., Hohlfeld, R. et al. Oral fingolimod (FTY720) vs placebo in relapsing-remitting multiple sclerosis: 24-month safety and tolerability results from a randomized, double-blind, placebo-controlled, multicenter phase III study (FREEDOMS). 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P06.171.
55. Khatri, B., Barkhof, F., Comi, G. et al. 24-month efficacy and safety outcomes from the TRANSFORMS extension study of oral fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis. 62nd Annu Meet Am Acad Neurol (AAN) (April 10-17, Toronto) 2010, Abst P03.125.